OPK Overview

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is2.75 USD with a low forecast of 2.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

OPKO Health Inc revenue for the last quarter amounts to 124.20M USD, decreased -17.18

OPKO Health Inc. EPS for the last quarter amounts to -0.07 USD, decreased -30.00

OPKO Health Inc (OPK) has 2275 emplpoyees as of June 20 2026.

Today OPK has the market capitalization of 1.07B USD.